iPCM – implementation of Personalised Cancer Medicine

iPCM is an academic sampling study based at Karolinska Institutet focuses on newly diagnosed advanced or metastatic solid tumors. Inclusion criteria: Patients newly diagnosed with metastatic solid cancer, or those who were treated for localized solid cancer and later diagnosed with metastatic disease. Exclusion criteria: Patients with metastatic cancer who have received ≥1 lines of systemic treatment and are over 80 years old. Coordinating PI: MD Dr. Jeff Yachnin.